-
1
-
-
67349208527
-
-
World Health Organization. Hepatitis B 2000. Accessed 24 Nov
-
World Health Organization. Hepatitis B 2000. http://www.who.int/ mediacentre/factsheets/fs204/en/ Accessed 24 Nov 2007.
-
(2007)
-
-
-
2
-
-
1642410856
-
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
-
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
-
(2004)
J Viral Hepat
, vol.11
, pp. 97-107
-
-
Lavanchy, D.1
-
3
-
-
33748114343
-
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
-
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-38.
-
(2006)
J Hepatol
, vol.45
, pp. 529-538
-
-
Perz, J.F.1
Armstrong, G.L.2
Farrington, L.A.3
Hutin, Y.J.4
Bell, B.P.5
-
4
-
-
34547488366
-
Risk and predictors of mortality associated with chronic hepatitis B infection
-
Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921-31.
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 921-931
-
-
Iloeje, U.H.1
Yang, H.I.2
Jen, C.L.3
Su, J.4
Wang, L.Y.5
You, S.L.6
-
5
-
-
19544391413
-
Lamivudine for patients with chronic hepatitis B and advanced liver disease
-
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
-
(2004)
N Engl J Med
, vol.351
, pp. 1521-1531
-
-
Liaw, Y.F.1
Sung, J.J.2
Chow, W.C.3
Farrell, G.4
Lee, C.Z.5
Yuen, H.6
-
6
-
-
24344478565
-
Molecular virology and the development of resistant mutants: Implications for therapy
-
Locarnini S. Molecular virology and the development of resistant mutants: Implications for therapy. Semin Liver Dis. 2005;25(Suppl 1):9-19.
-
(2005)
Semin Liver Dis.
, vol.25
, Issue.SUPPL. 1
, pp. 9-19
-
-
Locarnini, S.1
-
7
-
-
3242683269
-
Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B
-
Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat. 2004;11:349-57.
-
(2004)
J Viral Hepat
, vol.11
, pp. 349-357
-
-
Lin, S.M.1
Tai, D.I.2
Chien, R.N.3
Sheen, I.S.4
Chu, C.M.5
Liaw, Y.F.6
-
8
-
-
0033027690
-
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
-
Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-5.
-
(1999)
Hepatology
, vol.29
, pp. 971-975
-
-
Lin, S.M.1
Sheen, I.S.2
Chien, R.N.3
Chu, C.M.4
Liaw, Y.F.5
-
9
-
-
0035061788
-
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach
-
Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol. 2001;34:593-602.
-
(2001)
J Hepatol
, vol.34
, pp. 593-602
-
-
Cammà, C.1
Giunta, M.2
Andreone, P.3
Craxì, A.4
-
10
-
-
19944428400
-
Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival
-
Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105-14.
-
(2005)
Ann Intern Med
, vol.142
, pp. 105-114
-
-
Shiratori, Y.1
Ito, Y.2
Yokosuka, O.3
Imazeki, F.4
Nakata, R.5
Tanaka, N.6
-
11
-
-
33751514752
-
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
-
Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45-52.
-
(2007)
J Hepatol
, vol.46
, pp. 45-52
-
-
Lin, S.M.1
Yu, M.L.2
Lee, C.M.3
Chien, R.N.4
Sheen, I.S.5
Chu, C.M.6
-
12
-
-
0035468828
-
Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B
-
Tangkijvanich P, Thong-ngam D, Mahachai V, Kladchareon N, Suwangool P, Kullavanijaya P. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health. 2001;32:452-8.
-
(2001)
Southeast Asian J Trop Med Public Health
, vol.32
, pp. 452-458
-
-
Tangkijvanich, P.1
Thong-ngam, D.2
Mahachai, V.3
Kladchareon, N.4
Suwangool, P.5
Kullavanijaya, P.6
-
13
-
-
0035110693
-
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B
-
Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306-13.
-
(2001)
J Hepatol
, vol.34
, pp. 306-313
-
-
Papatheodoridis, G.V.1
Manesis, E.2
Hadziyannis, S.J.3
-
14
-
-
20144388156
-
Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma
-
Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int. 2005;25:220-5.
-
(2005)
Liver Int.
, vol.25
, pp. 220-225
-
-
Mahmood, S.1
Niiyama, G.2
Kamei, A.3
Izumi, A.4
Nakata, K.5
Ikeda, H.6
-
16
-
-
0028659004
-
Operating characteristics of a rank correlation test for publication bias
-
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
-
(1994)
Biometrics
, vol.50
, pp. 1088-1101
-
-
Begg, C.B.1
Mazumdar, M.2
-
17
-
-
0032032927
-
Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study
-
Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer. 1998;82:827-35.
-
(1998)
Cancer
, vol.82
, pp. 827-835
-
-
Ikeda, K.1
Saitoh, S.2
Suzuki, Y.3
Kobayashi, M.4
Tsubota, A.5
Fukuda, M.6
-
18
-
-
20244368049
-
Hepatitis B virus-related hepatocellular carcinogenesis and its prevention
-
Ikeda K, Arase Y, Kobayashi M, Someya T, Hosaka T, Saitoh S, et al. Hepatitis B virus-related hepatocellular carcinogenesis and its prevention. Intervirology. 2005;48:29-38.
-
(2005)
Intervirology
, vol.48
, pp. 29-38
-
-
Ikeda, K.1
Arase, Y.2
Kobayashi, M.3
Someya, T.4
Hosaka, T.5
Saitoh, S.6
-
19
-
-
0033179742
-
Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial
-
Mazzella G, Saracco G, Festi D, Rosina F, Marchetto S, Jaboli F, et al. Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial. Am J Gastroenterol. 1999;94:2246-50.
-
(1999)
Am J Gastroenterol
, vol.94
, pp. 2246-2250
-
-
Mazzella, G.1
Saracco, G.2
Festi, D.3
Rosina, F.4
Marchetto, S.5
Jaboli, F.6
-
20
-
-
0034124826
-
Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood
-
Fujisawa T, Komatsu H, Inui A, Sogo T, Miyagawa Y, Fujitsuka S, et al. Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. J Pediatr Gastroenterol Nutr. 2000;30:201-6.
-
(2000)
J Pediatr Gastroenterol Nutr.
, vol.30
, pp. 201-206
-
-
Fujisawa, T.1
Komatsu, H.2
Inui, A.3
Sogo, T.4
Miyagawa, Y.5
Fujitsuka, S.6
-
21
-
-
0032560376
-
Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
-
International Interferon-alpha Hepatocellular Carcinoma Study Group
-
International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet. 1998;351:1535-9.
-
(1998)
Lancet
, vol.351
, pp. 1535-1539
-
-
-
22
-
-
34347234518
-
Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients
-
Lu HY, Zhuang LW, Yu YY, Ivan H, Si CW, Zeng Z, et al. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol. 2007;13:2878-82.
-
(2007)
World J Gastroenterol
, vol.13
, pp. 2878-2882
-
-
Lu, H.Y.1
Zhuang, L.W.2
Yu, Y.Y.3
Ivan, H.4
Si, C.W.5
Zeng, Z.6
-
23
-
-
0027378724
-
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
-
Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312-23.
-
(1993)
Ann Intern Med.
, vol.119
, pp. 312-323
-
-
Wong, D.K.1
Cheung, A.M.2
O'Rourke, K.3
Naylor, C.D.4
Detsky, A.S.5
Heathcote, J.6
-
24
-
-
0027313416
-
Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature
-
Tinè F, Liberati A, Craxì A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J Hepatol. 1993;18:154-62.
-
(1993)
J Hepatol
, vol.18
, pp. 154-162
-
-
Tinè, F.1
Liberati, A.2
Craxì, A.3
Almasio, P.4
Pagliaro, L.5
-
25
-
-
0141637207
-
Interferon-alpha for HBeAg-positive chronic hepatitis B
-
Craxì A, Di Bona D, Cammà C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol. 2003;39(Suppl 1):S99-105.
-
(2003)
J Hepatol
, vol.39
, Issue.SUPPL. 1
-
-
Craxì, A.1
Di Bona, D.2
Cammà, C.3
-
26
-
-
0026658646
-
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
-
de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103:1630-5.
-
(1992)
Gastroenterology
, vol.103
, pp. 1630-1635
-
-
de Jongh, F.E.1
Janssen, H.L.2
de Man, R.A.3
Hop, W.C.4
Schalm, S.W.5
van Blankenstein, M.6
-
27
-
-
84984555343
-
Hepatitis B e antigen and the risk of hepatocellular carcinoma
-
Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168-74.
-
(2002)
N Engl J Med
, vol.347
, pp. 168-174
-
-
Yang, H.I.1
Lu, S.N.2
Liaw, Y.F.3
You, S.L.4
Sun, C.A.5
Wang, L.Y.6
-
28
-
-
34548806374
-
Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients
-
Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007;46:690-8.
-
(2007)
Hepatology
, vol.46
, pp. 690-698
-
-
Hui, C.K.1
Leung, N.2
Shek, T.W.3
Yao, H.4
Lee, W.K.5
Lai, J.Y.6
-
29
-
-
0038045171
-
Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
-
Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298-305.
-
(2003)
J Viral Hepat
, vol.10
, pp. 298-305
-
-
Cooksley, W.G.1
Piratvisuth, T.2
Lee, S.D.3
Mahachai, V.4
Chao, Y.C.5
Tanwandee, T.6
-
30
-
-
33846938792
-
Genotype B and younger patient age associated with better response to low-dose therapy: A trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China
-
Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, et al. Genotype B and younger patient age associated with better response to low-dose therapy: A trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44:541-8.
-
(2007)
Clin Infect Dis.
, vol.44
, pp. 541-548
-
-
Zhao, H.1
Kurbanov, F.2
Wan, M.B.3
Yin, Y.K.4
Niu, J.Q.5
Hou, J.L.6
-
31
-
-
21244447705
-
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
-
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-95.
-
(2005)
N Engl J Med.
, vol.352
, pp. 2682-2695
-
-
Lau, G.K.1
Piratvisuth, T.2
Luo, K.X.3
Marcellin, P.4
Thongsawat, S.5
Cooksley, G.6
-
32
-
-
30344457555
-
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
-
Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166:49-56.
-
(2006)
Arch Intern Med
, vol.166
, pp. 49-56
-
-
Lim, S.G.1
Ng, T.M.2
Kung, N.3
Krastev, Z.4
Volfova, M.5
Husa, P.6
-
33
-
-
0037468421
-
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
-
Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16.
-
(2003)
N Engl J Med.
, vol.348
, pp. 808-816
-
-
Marcellin, P.1
Chang, T.T.2
Lim, S.G.3
Tong, M.J.4
Sievert, W.5
Shiffman, M.L.6
-
34
-
-
0033592764
-
Lamivudine as initial treatment for chronic hepatitis B in the United States
-
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-63.
-
(1999)
N Engl J Med.
, vol.341
, pp. 1256-1263
-
-
Dienstag, J.L.1
Schiff, E.R.2
Wright, T.L.3
Perrillo, R.P.4
Hann, H.W.5
Goodman, Z.6
-
35
-
-
0032499913
-
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
-
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8.
-
(1998)
N Engl J Med.
, vol.339
, pp. 61-68
-
-
Lai, C.L.1
Chien, R.N.2
Leung, N.W.3
Chang, T.T.4
Guan, R.5
Tai, D.I.6
-
36
-
-
33750499091
-
Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine
-
Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006;101:2523-9.
-
(2006)
Am J Gastroenterol
, vol.101
, pp. 2523-2529
-
-
Flink, H.J.1
Hansen, B.E.2
Heathcote, E.J.3
Feinman, S.V.4
Simsek, H.5
Karayalcin, S.6
-
37
-
-
34548311958
-
Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
-
Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007;46:388-94.
-
(2007)
Hepatology
, vol.46
, pp. 388-394
-
-
Buster, E.H.1
Hansen, B.E.2
Buti, M.3
Delwaide, J.4
Niederau, C.5
Michielsen, P.P.6
-
38
-
-
14844321911
-
Hepatitis B virus: Significance of genotypes
-
Schaefer S. Hepatitis B virus: Significance of genotypes. J Viral Hepat. 2005;12:111-24.
-
(2005)
J Viral Hepat
, vol.12
, pp. 111-124
-
-
Schaefer, S.1
-
39
-
-
4644219526
-
Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma
-
Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494-8.
-
(2004)
Gut
, vol.53
, pp. 1494-1498
-
-
Chan, H.L.1
Hui, A.Y.2
Wong, M.L.3
Tse, A.M.4
Hung, L.C.5
Wong, V.W.6
-
40
-
-
0036896130
-
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C
-
Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002;36:1425-30.
-
(2002)
Hepatology
, vol.36
, pp. 1425-1430
-
-
Wai, C.T.1
Chu, C.J.2
Hussain, M.3
Lok, A.S.4
-
41
-
-
34347327007
-
Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance
-
Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol. 2007;79:1055-63.
-
(2007)
J Med Virol
, vol.79
, pp. 1055-1063
-
-
Hou, J.1
Schilling, R.2
Janssen, H.L.3
Hansen, B.E.4
Heijtink, R.5
Sablon, E.6
-
42
-
-
34247538953
-
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
-
Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56:699-705.
-
(2007)
Gut
, vol.56
, pp. 699-705
-
-
Bonino, F.1
Marcellin, P.2
Lau, G.K.3
Hadziyannis, S.4
Jin, R.5
Piratvisuth, T.6
-
43
-
-
33644882231
-
Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype
-
Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL, et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006;101:297-303.
-
(2006)
Am J Gastroenterol
, vol.101
, pp. 297-303
-
-
Flink, H.J.1
van Zonneveld, M.2
Hansen, B.E.3
de Man, R.A.4
Schalm, S.W.5
Janssen, H.L.6
-
44
-
-
4544239807
-
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
-
Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-17.
-
(2004)
N Engl J Med.
, vol.351
, pp. 1206-1217
-
-
Marcellin, P.1
Lau, G.K.2
Bonino, F.3
Farci, P.4
Hadziyannis, S.5
Jin, R.6
-
45
-
-
29944436855
-
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
-
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
-
(2006)
JAMA
, vol.295
, pp. 65-73
-
-
Chen, C.J.1
Yang, H.I.2
Su, J.3
Jen, C.L.4
You, S.L.5
Lu, S.N.6
-
46
-
-
13844322073
-
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men
-
Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst. 2005;97:265-72.
-
(2005)
J Natl Cancer Inst.
, vol.97
, pp. 265-272
-
-
Yu, M.W.1
Yeh, S.H.2
Chen, P.J.3
Liaw, Y.F.4
Lin, C.L.5
Liu, C.J.6
-
47
-
-
0036614299
-
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
-
Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522-7.
-
(2002)
Hepatology
, vol.35
, pp. 1522-1527
-
-
Hsu, Y.S.1
Chien, R.N.2
Yeh, C.T.3
Sheen, I.S.4
Chiou, H.Y.5
Chu, C.M.6
|